Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imatinib vs Interferon in KIT-mutated Melanoma
NCT01782508Phase 2
Key facts
- Status
- Unknown
- Start
- Aug 2012
- Primary completion
- Dec 2013
- Countries
- 1
- Sponsor
- Peking University Cancer Hospital & Institute
- Modality
- Small Molecules
- Drugs
- imatinib
- Conditions
- melanoma
01
Overview
Phase 2, randomised, open-label trial of imatinib in melanoma (2 arms), sponsored by Peking University Cancer Hospital & Institute. Primary endpoint: Relapse Free Survival at 18 months. Status: unknown.
02
Design
2 arms- Study design
- RandomizedOpen-label
Imatinib Arm
Imatinib 400mg daily for 1 year
Interferon Arm
High dose Interferon for 1 year
03
Who it enrols
Patients with resected AJCC stage IIB to IIIC melanoma harboring a c-kit mutation, ECOG 0-1, and adequate organ function.
04
Endpoints
Primary
Relapse Free Survival
Secondary
Overall Survival
Beyond the preview
Go deeper on NCT01782508.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01782508.